摘要
【目的】探讨索利那新改善儿童特发性膀胱过度活动症症状的疗效分析。【方法】收集2022年3月至2023年3月于我院泌尿外科门诊就诊的67例特发性膀胱过度活动症患儿的临床资料,所有患儿均经过至少2周行为治疗症状无明显改善,其中52例予索利那新(每天5 mg)口服(服药组),并根据患儿是否伴有尿失禁症状分为干性组(27例)与湿性组(25例),剩余15例拒绝服药的患儿继续维持行为治疗(观察组)。自服药开始随访3个月,分别收集每名患儿服药前、服药2周、服药4周、服药8周、服药12周连续3 d排尿日记及膀胱过度活动症症状评分表(OABSS),并记录病程中患儿不良反应情况。【结果】67例患儿均完成随访,其中44例患儿治愈(观察组3人治愈,12人未治愈;服药组41人治愈,11人未治愈),4例出现不良反应。(1)服药组较观察组随访末期OABSS评分显著降低(Z=4.524,P<0.001);观察组与服药组的治愈率分别20%、78.8%,存在显著差异(χ^(2)=15.367,P<0.001);(2)随随访时间延长,服药组患儿平均每次排尿量增加(F=9.707,P<0.001)、日平均排尿次数降低(F=3.837,P=0.009)、尿急评分(χ^(2)=482.835,P<0.001)下降;(3)干性组与湿性组随访3个月治愈率分别为81.5%、76%,差异无统计学意义(χ^(2)=0.234,P=0.629)。【结论】特发性膀胱过度活动症患儿口服索利那新(每日5 mg)可显著减少日平均排尿次数,增加平均每次排尿量,缓解尿急症状,不良反应较少。但是对于治愈湿性患儿尿失禁症状疗效不显著。
【Objective】To explore the efficacy of Solifenacin in the treatment of children with idiopathic overactive bladder(OAB).【Methods】The study included 67 children with idiopathic OAB treated in the urology clinic of our hospital from March 2022 to March 2023.After at least 2-week-long behavioral therapy showed no significant therapeutic effect,52 of the cases in the trial group were given oral Solifenacin 5 mg once daily and the other 15 cases in the control group con-tinued the behavioral therapy.The cases in trial group were subdivided into OAB-dry group(27 cases without urinary in-continence)and OAB-wet group(25 cases with urinary incontinence).The 3-day micturition diary,OAB Symptom Scores(OABSS)and the adverse reactions were recorded and analyzed before,at Weeks 2,4,8 and 12 after the treat-ment.【Results】Of all the 67 cases who completed a 3-month follow-up,44 were cured including 41 in the trial group and 3 in the control group,4 presented with adverse reactions.After the 3-month follow-up,the OABSS declined markedly in trial group than in control group(Z=4.524,P<0.001);the cure rates in trial group and control group are 78.8%and 20%respectively,with significant difference(χ^(2)=15.367,P<0.001).At each follow-up,we found increased mean voided vol-ume(F=9.707,P<0.001),reduced mean voiding frequency during daytime(F=3.837,P=0.009)and decreased voiding urgency(χ^(2)=482.835,P<0.001).After the 3-month follow-up,the cure rates in OAB-dry group and OAB-wet group are 81.5%and 76%respectively,with no significant difference(χ^(2)=0.234,P=0.629).【Conclusions】In children with idiopath-ic OAB,oral Solifenacin 5 mg once daily could significantly increase mean voided volume,reduce mean voiding frequency during daytime,relieve symptoms of urinary urgency and lead to fewer adverse reactions,but is not significantly effective for the treatment of urinary incontinence in OAB-wet children.
作者
何萍
张晔
张殷
孙起航
尤龙
潮敏
HE Ping;ZHANG Ye;ZHANG Yin;SUN Qihang;YOU Long;CHAO Min(Anhui Provincial Children’sHospital,Anhui Medical University,Hefei,Anhui 230051,China;The Fifth School of Clinical Medicine,Anhui Medical University,Hefei,Anhui 230051,China)
出处
《中山大学学报（医学科学版）》
CAS
CSCD
北大核心
2024年第3期337-343,共7页
Journal of Sun Yat-Sen University:Medical Sciences
基金
安徽省科技厅临床医学研究转化专项项目(202304295107020066)。
关键词
膀胱过度活动症
尿失禁
尿急
儿童
索利那新
overactive bladder(OAB)
urinary incontinence
urinary urgency
children
Solifenacin
